Sage Therapeutic Com
(NQ:
SAGE
)
7.250
-0.190 (-2.55%)
Streaming Delayed Price
Updated: 10:47 AM EDT, Sep 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sage Therapeutic Com
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
January 31, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces Changes to Board of Directors
January 08, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
January 02, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
The Latest Analyst Ratings for Sage Therapeutics
December 12, 2023
Via
Benzinga
Analyst Ratings for Sage Therapeutics
November 08, 2023
Via
Benzinga
Why Sage Therapeutics Stock Sank Today
November 07, 2023
A secondary stock sale and underwhelming quarterly results sent investors to the off-ramp.
Via
The Motley Fool
5 Biotech stocks tapping into unmet mental health treatment needs
December 20, 2023
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.
Via
MarketBeat
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
December 14, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
December 14, 2023
From
Biogen Inc.
Via
GlobeNewswire
The Latest Analyst Ratings for Sage Therapeutics
October 13, 2023
Via
Benzinga
Where Sage Therapeutics Stands With Analysts
September 07, 2023
Via
Benzinga
Sage Therapeutics to Present at Upcoming November Investor Conferences
November 08, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 07, 2023
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
Via
Benzinga
Earnings Scheduled For November 7, 2023
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
November 07, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 24, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
October 18, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
September 08, 2023
Via
Benzinga
3 Healthcare Stocks to Sell in September Before They Crash & Burn
September 06, 2023
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse.
Via
InvestorPlace
Sage Therapeutics to Present at Upcoming September Investor Conferences
September 06, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating DigitalOcean, and Sage and Encourages Investors to Contact the Firm
September 01, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
September 01, 2023
Via
ACCESSWIRE
Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment
August 31, 2023
The company is now focusing on its launch in postpartum depression.
Via
Investor's Business Daily
Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement
August 31, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Blink, Lovesac, and Sage and Encourages Investors to Contact the Firm
August 27, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
3 Very Oversold Pharma Stocks to Buy Right Now
August 24, 2023
Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy.
Via
InvestorPlace
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
August 24, 2023
The pharmaceutical company's growth prospects have taken a big hit.
Via
The Motley Fool
SAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating Sage Therapeutics, Inc. on Behalf of Sage Stockholders and Encourages Investors to Contact the Firm
August 21, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
SAGE INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
August 14, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.